Mariner LLC Invests $67,000 in LifeMD, Inc. (NASDAQ:LFMD)

Mariner LLC acquired a new stake in shares of LifeMD, Inc. (NASDAQ:LFMD) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 13,590 shares of the company’s stock, valued at approximately $67,000.

Several other institutional investors also recently modified their holdings of LFMD. AXQ Capital LP bought a new position in LifeMD during the 4th quarter valued at about $57,000. Quantbot Technologies LP purchased a new position in shares of LifeMD during the fourth quarter valued at approximately $59,000. Prudential Financial Inc. lifted its position in LifeMD by 19.3% during the fourth quarter. Prudential Financial Inc. now owns 13,605 shares of the company’s stock valued at $67,000 after purchasing an additional 2,200 shares during the period. Magnus Financial Group LLC boosted its holdings in LifeMD by 31.1% in the fourth quarter. Magnus Financial Group LLC now owns 16,000 shares of the company’s stock worth $79,000 after purchasing an additional 3,792 shares during the last quarter. Finally, Wells Fargo & Company MN boosted its holdings in LifeMD by 44.7% in the fourth quarter. Wells Fargo & Company MN now owns 18,732 shares of the company’s stock worth $93,000 after purchasing an additional 5,791 shares during the last quarter. 35.52% of the stock is owned by hedge funds and other institutional investors.

LifeMD Stock Up 1.2 %

NASDAQ LFMD opened at $8.26 on Friday. LifeMD, Inc. has a 52 week low of $3.99 and a 52 week high of $9.87. The company has a market capitalization of $363.18 million, a P/E ratio of -12.91 and a beta of 2.22. The stock’s 50-day moving average price is $5.86 and its 200-day moving average price is $5.68.

LifeMD (NASDAQ:LFMD) last issued its quarterly earnings results on Tuesday, May 6th. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of ($0.04) by $0.05. The firm had revenue of $65.70 million for the quarter, compared to analysts’ expectations of $62.47 million. Research analysts anticipate that LifeMD, Inc. will post -0.56 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on LFMD shares. HC Wainwright restated a “buy” rating and issued a $14.00 price target on shares of LifeMD in a research note on Wednesday, April 30th. B. Riley upgraded LifeMD to a “strong-buy” rating in a research note on Tuesday, March 11th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $15.00 price target on shares of LifeMD in a research report on Tuesday, March 11th. One equities research analyst has rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $11.00.

Insider Buying and Selling at LifeMD

In related news, CEO Justin Schreiber sold 50,000 shares of the stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $7.55, for a total transaction of $377,500.00. Following the completion of the sale, the chief executive officer now owns 2,653,715 shares in the company, valued at approximately $20,035,548.25. This trade represents a 1.85 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CMO Jessica Friedeman sold 30,000 shares of the business’s stock in a transaction that occurred on Friday, March 14th. The stock was sold at an average price of $5.66, for a total value of $169,800.00. Following the completion of the transaction, the chief marketing officer now directly owns 170,000 shares in the company, valued at approximately $962,200. This represents a 15.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 151,995 shares of company stock valued at $1,101,922 over the last ninety days. 15.97% of the stock is currently owned by company insiders.

About LifeMD

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.